Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma by unknown
ORIGINAL RESEARCH ARTICLE Open Access
Fluticasone furoate/Vilanterol 92/22 μg
once-a-day vs Beclomethasone
dipropionate/ Formoterol 100/6 μg
b.i.d.: a 12-week cost analysis in
mild-to-moderate asthma
Roberto W. Dal Negro1*, Chiara Distante2, Luca Bonadiman3, Paola Turco3 and Sergio Iannazzo2
Abstract
Background: Asthma is a disease with high cost for the National Health Service. Two of the most recent LABA/ICS
combinations for persistent bronchial asthma are Beclomethasone dipropionate/Formoterol (B/F) delivered via the
Nexthaler device and Fluticasone furoate/Vilanterol (F/V) delivered via the Ellipta device. No comparison has been
carried out yet in terms of cost analysis in asthma, to our knowledge. Aim of the present monocentric,
observational, retrospective study was to calculate and compare the costs of mild-to-moderate asthma patients
assuming B/F 100/6 μg b.i.d. to those of patients assuming F/V 92/22 μg once-a-day over a 12-week treatment
period from the Italian National Health Service perspective.
Methods: Data were obtained automatically and anonymously from the institutional database of the Lung Unit of
the Specialist Medical Centre (CEMS), Verona, Italy, UNI EN ISO 9001-2008 validated. FEV1 values, number of relapses,
healthcare resources as hospitalizations due to asthma relapses, days of hospitalization, general practitioner (GP),
specialist visits, and days of inactivity, were recorded over the study period together with the use of extra medications
(systemic steroids and antibiotics). In order to compare the outcomes achieved in both groups, the propensity score
matching method was used in STATA, and statistical significance was accepted for p < 0.05.
Results: Clinical data of 77 patients treated with B/F b.i.d (Group A) and of 40 patients treated with F/V 92/22 μg
once-a-day (Group B) were selected. The PS-matching process, designed as matching on the baseline covariates,
gender, age, FEV1 and comorbidities, returned a cohort of 40 group A patients of the entire cohort matched with
40 patients of group B, fully comparable for demographics and clinical characteristics. In the PS-matched cohort, the
mean (±SE) number of relapses per patient during the follow-up was 0.53 (±0.12) in group A and 0.28 (±0.07) in group
B. In group A, n = 25 (62.50 %), n = 9 (22.50 %), and n = 6 (15 %) patients had 0, 1, 2 relapses, respectively. In group B,
n = 29 (72.50 %), and n = 11 (27.50 %) had 0 and 1 relapse, respectively. Over the study period, the average number of
hospitalizations per patient was 0.15 (±0.06), with 0.28 (±0.12) days of hospitalization in group A, and 0.08 (±0.04) with
0.08 (±0.04) days of hospitalization in group B, respectively. The difference between the two groups in terms of FEV1(L)
improvement vs baseline was 0.11 in favour of group B (p = 0.007). When results were compared, the improvement in
lung function obtained in group B proved significantly higher both in terms of absolute FEV1 and of FEV1 % predicted.
The mean (±SE) cost of hospitalizations per patient was € 345.30 (±133.23) in group A and € 172.65 (±98.18) in group B,
respectively, with a mean not significant difference of - € 172.65 in favour of group B (p = 0.9). In particular, the
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mean (±SE) cost for visits per patient was € 26.82 (±3.73) in group A and € 11.36 (±2.30) in group B (p = 0.002),
and the mean cost for rescue medications per patient was € 35.24 (±6.93) in group A, and € 18.73 (±3.38) in
group B, respectively (p = 0.05).
Conclusions: Even if both ICS/LABA combinations were checked over a limited period of time, they seem
characterized by a different profile in terms of effect on lung function and economic impact on mild-to-
moderate asthma. The once-daily inhalation of combined Fluticasone furoate/Vilanterol 92/22 μg
showed the potential for enhanced clinical outcomes and reduced costs when compared to Beclomethasone
dipropionate/Formoterol 100/6 μg b.i.d.
Keywords: Asthma cost Beclomethasone dipropionate/Formoterol, Bronchial asthma, Cost analysis, Fluticasone
furoate/Vilanterol
Background
Bronchial asthma is a chronic inflammatory disease of the
airways. It is characterized by airflow limitation, usually
reversible spontaneously or following therapy, bronchial
hyper-responsiveness and accelerated decline in lung
function, which may progress to irreversible obstruction
of the airways [1].
The underlying mechanism responsible for asthma is
the excessive presence and activation of inflammatory
cells within the mucosal, muscular and vascular struc-
tures of the airways, which cause the release of inflam-
matory mediators and the remodeling of the airways.
Clinically it manifests by the appearance and recurrence
of cough, dyspnea, wheezing (at rest and/or by physical
exertion), and chest tightness [1]. The clinical expression
of the disease varies among individuals and in the same
patient over time [2].
According to WHO estimates, 235 million people suffer
from asthma. The Italian National Institute of Statistics
(ISTAT) survey on health and use of health services esti-
mated a prevalence of asthma of 4.2 % (female 4.3 %, male
4.2 %) in Italy in 2012 [3].
The severity of the disease is based on the frequency of
symptoms, value of forced expiratory volume in 1 s
(FEV1), variability of peak expiratory flow (PEF), and
Quality of Life. On this basis there are four levels of
asthma severity: mild intermittent, mild persistent, moder-
ate persistent and severe persistent.
Asthma is a disease with high cost for the Italian
National Health Service. The main costs are indirect and
for hospitalization [4]. The total burden of asthma was
estimated to be in Italy about 5 billion Euro per year.
Asthma cannot be cured, but appropriate management
can control the disorder and enable people to enjoy a
good quality of life [2]. The goal of asthma therapy is to
achieve and maintain the control of the disease.
The therapeutic strategy includes two main categories
of drugs: controller and rescue medications. The con-
troller medications must be taken regularly to keep the
disease under control. The rescue medications relieve
the acute bronchoconstriction and related symptoms.
Since asthma is an inflammatory disease, inhaled corti-
costeroids (ICS) are the most effective controller medi-
cations currently available and represent the first choice
of treatment, to which long-acting beta2-agonists bron-
chodilators (LABA) can be added. The combination of
these two categories of drugs is the recommended thera-
peutic strategy for persistent asthma [1].
Two of the most recent LABA/ICS combinations for
persistent bronchial asthma are the Fluticasone furoate/
Vilanterol (F/V) 92/22 μg delivered via the Ellipta device
[5–7] and the Beclomethasone dipropionate/Formoterol
100/6 μg (B/F) delivered via the Nexthaler device [8–10].
While the former combination covers 24 h and is assumed
at once-a-day regimen, the latter has to be assumed twice
daily (bis in die, b.i.d.).
Although several studies investigated both the effective-
ness and the safety of these two ICS/LABA combinations,
to our knowledge no cost comparison has been carried
out yet.
Objective
The purpose of the present study was to estimate and
compare the costs of mild-to-moderate asthma patients
assuming Beclomethasone dipropionate/Formoterol 100/
6 μg b.i.d. to those of patients assuming Fluticasone furo-
ate/Vilanterol 92/22 μg once-a-day over a 12-week treat-
ment period from the Italian National Health Service
perspective.
Methods
The study was an observational, retrospective analysis on
asthmatic patients referring over the period February-
September 2015 to the Lung Unit of the Specialist Medical
Centre (CEMS), Verona, Italy.
Data were obtained automatically and anonymously
from the institutional, UNI EN ISO 9001-2008 validated
database, and the classic Boolean algebraic formulas
were used for selections [11]. Selection criteria were:
asthma subjects of both genders >18 years of age; non-
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smoker; with a normal cognitive function; in a stable re-
spiratory condition (spirometrically assessed) in the last
2 weeks before the study start; assuming B/F 100/6 μg
b.i.d (Group A) or F/V 92/22 μg once-a-day (Group B)
for 12 (±2) weeks. In baseline sex, age, the absolute and
the % predicted values of forced expiratory volume in
1 s (FEV1 in Litres and FEV1 as % predicted), and co-
morbidities of the patients were recorded. All patients
were followed for 12 (±2) weeks. FEV1 values, number
of relapses, healthcare resources as hospitalizations due
to asthma relapses, days of hospitalization, general prac-
titioner (GP), specialist visits, and days of inactivity were
recorded over the study period. The adherence to both
treatments was recorded and expressed in % inhalations
vs expected number of inhalations over the study period.
The use of extra medications (systemic steroids and anti-
biotics) was also recorded.
In order to compare the outcomes of the patients of
both groups, the propensity score (PS) matching
method [12] was used in STATA [13]. Statistical signifi-
cance was accepted for p < 0.05. This statistical proced-
ure reduces the bias in estimation of treatment effects
with observational datasets. The propensity score
matching method summarizes pretreatment character-
istics of each subject into a single-index variable (the
propensity score) that makes the matching feasible. In
this study, a logit regression to estimate the propensity
score on the baseline covariates age, sex, FEV1(%) and
presence of comorbidities was used. Furthermore, the
propensity score matching was performed without re-
placement, i.e. each of 40 patients of the Group B was
matched with only one patient of the Group A.
Costs were analysed and reported as mean values per pa-
tient over the study period, in terms of: 1) hospitalization
costs; 2) visits costs; 3) rescue-medications costs, and 4)
main treatment (controller medication) costs.
Hospitalization cost was evaluated as the mean cost
for asthma relapse according to national diagnosis-
related group (DRG) tariffs [14], weighted for the fre-
quency reported during the 12-week study. The cost of
hospitalization due to asthma relapse in the presence of
serious comorbid disease was € 2, 537 (DRG 96), while
the cost in the absence of serious comorbid disease was
€1,832 (DRG 97).
GP visit cost was estimated in €15.17 based on a pub-
lished cost study inflated to Euro 2015 with the ISTAT
consumer price index [15, 16]. The cost for specialist’s
visit was €20.66, derived from national inpatient tariffs
(Code 89.7) [17].
Cost of steroids and antibiotics (rescue medications)
was estimated considering the ex-manufactory pack-
prices [18] and the cycles observed of medications. The
unit cost of one cycle of steroids and antibiotics was es-
timated in € 12.40 and € 42.00 respectively, considering
only the ex-manufactory pack-prices [18]. The cost of
drugs was estimated considering the ex-manufactory
pack prices [18] and the adherence to the treatments.
The unit price of B/F was € 31.80 for a pack containing
an inhaler with 120 doses, and the daily dose was two
inhalations/day. The unit price of F/V was € 30.00 for a
pack containing an inhaler with 30 doses, and the daily
dose was one inhalations/day.
Results
Clinical data of 77 patients treated with B/F 100/6 μg
b.i.d (Group A) and of 40 patients treated with F/V 92/
22 μg once-a-day (Group B) were obtained.
The demographics and clinical characteristics of the en-
tire cohort are summarized in Table 1. At the baseline,
male prevalence was 33.8 % in group A and 37.5 % in
group B. Mean (±SE) age was 51.87 (±1.60) in group A,
and 50.18 (±2.43) in group B. Mean (±SE) FEV1 in litres
(L) was 2.42 (±0.09) in group A, and 2.51 ((±0.12) in
group B. Mean (±SE) FEV1% pred. was 82.23 % (±1.14)
and 81.93 % (±2.00) in group A and B, respectively.
Patients with perennial allergy were 61.0 % (47/77) in
group A, and 62.5 % (25/40) in group B, while those with
seasonal allergy were 39.0 % (30/77) in group A, and
37.5 % (15/40) in group B, respectively. The percentage of
patients with established comorbidities was 37.7 % in
group A, and 42.5 % in group B. The following comorbid
diseases were equally reported in both groups: arterial
Table 1 Baseline characteristics of the entire cohort and of the PS-matched cohort
Overall cohort PS-matched cohort
Group A Group B Difference
Group B – Group A
Group A Group B Difference
Group B – Group A
n 77 40 40 40
Males (n) (%) 26 (33.8 %) 15 (37.5 %) -11 (-3.80 %) 15 (37.5 %) 15 (37.5 %) 0
Mean Age (years) (±SE) 51.87 (±1.60) 50.18 (±2.43) -1.69 49.40 (±2.05) 50.18 (±2.43) 0.78
Mean FEV1 % predicted (±SE) 82.23 (±1.14) 81.93 (±2.00) -0.30 82.40 (±1.63) 81.93 (±2.00) -0.47
Comorbidities (% of patients) 37.7 % 42.5 % -4.80 % 42.5 % 42.5 % 0
Forced expiratory volume in 1 s, predicted values (FEV1%)
Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day
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hypertension, kyphoscoliosis, obesity, severe depression,
AIDS, diabetes mellitus, severe osteoporosis and ischemic
heart disease. In particular, arterial hypertension was the
most prevalent comorbidity in both groups: 12.5 % in
group A, and 10.4 % in group B, respectively).
The PS-matching process, designed as matching on
the baseline covariates, gender, age, FEV1 and comorbid-
ities, returned a cohort of 40 group A patients of the en-
tire cohort matched with 40 patients of group B.
The demographics and clinical characteristics of the
PS-matched cohort at the baseline are described in
Table 1. The male prevalence in group A was the same
as in group B (37.5 %). Mean age (±SE) was 49.40
(±2.05) in group A and 50.18 (±2.43) in group B, re-
spectively. Mean (±SE) FEV1% pred. was 82.40 % (±1.63)
in group A and 81.93 % (±2.00) in group B. The pres-
ence of comorbidities was balanced (42.5 %) in both
groups.
In the PS-matched cohort, the mean (±SE) number of
relapses per patient during the follow-up was 0.53 (±0.12)
in group A and 0.28 (±0.07) in group B. In group A, n =
25 (62.50 %), n = 9 (22.50 %), and n = 6 (15 %) patients
had 0, 1, 2 relapses, respectively. In group B, n = 29
(72.50 %), and n = 11 (27.50 %) had 0 and 1 relapse, re-
spectively (Table 2).
Over the study period, the average (±SE) number of
hospitalizations per patient was 0.15 (±0.06), with 0.28
(±0.12) days of hospitalization in group A, and 0.08
(±0.04) with 0.08 (±0.04) days of hospitalization in group
B, respectively. n = 34 patients (85 %) had 0 days of
hospitalization; n = 3 (7.5 %) had 1 day; n = 1 (2.5 %) had
2 days, and n = 2 (5 %) patients had 3 days of
hospitalization in group A, while n = 37 (92.5 %) and n = 3
(7.50 %) patients had 0 and 1 day of hospitalization, re-
spectively in group B, (Table 2).
The mean number of cycles of steroids was 0.73 in
group A and 0.33 in group B. The mean number of cy-
cles of antibiotics was 0.33 and 0.63 and 0.35 in group A
and group B, respectively.
The adherence to the treatments [168 (±14) expected
doses with treatment A and 84 (±14) expected doses
with treatment B] was 82.2 % in group A and 93.3 % in
group B, respectively. In other words, 30 doses were
skipped (approximately corresponding to 15 days of
treatment) in group A, and to 6 doses were skipped in
group B (corresponding to 6 days of treatment).
In order to evaluate the efficacy of B/F and F/V treat-
ments, FEV1 in litres (L) and FEV1 % predicted values
were compared at baseline and at the end of the study
period in the PS-matched cohort (Table 3).
In group A mean (±SE) FEV1 (L) value was 2.52 (±0.13)
at baseline and 2.62 (±0.12) at the end of the study, and
the difference vs baseline was 0.10. In this group, mean
FEV1 % pred. was 82.40 % (±1.63) and 87.08 % (±1.58) at
baseline and at the end of the study, respectively; the FEV1
% pred. difference vs baseline was 4.68 %.
In group B the mean (±SE) FEV1 (L) was 2.51 (±0.12)
at baseline and 2.72 (±0.13) at the end of the study. The
FEV1 difference vs baseline was 0.21. In this group,
mean (±SE) FEV1 % pred. was 81.93 % (±2.00) and
89.50 % (±2.64) at baseline and at the end of the study,
respectively; the FEV1 % pred. difference vs baseline was
7.57 %.
The difference between the two groups in terms of
FEV1 (L) improvement vs baseline was 0.11 in favour of
group B (p = 0.007). The corresponding difference in
terms of FEV1 % pred. improvement vs baseline was
2.89 in favour of group B (p = 0.04).
In the PS-matched cohort, the mean (±SE) cost of
hospitalizations per patient was € 345.30 (±133.23) in
group A and € 172.65 (±98.18) in group B, respectively,
with a mean difference of - € 172.65 in favour of group
B. The mean (±SE) cost for GP visits per patient was €
12.88(±2.27) in group A and € 5.68(±1.77) in group B,
with a mean difference - € 7.20 in favour of group B.
The mean (±SE) cost for specialist visits per patient was
€ 13.95 (±2.27) in group A and € 5.68 (±1.48) in group
B, with a mean difference - € 8.26 (Table 4).
Table 2 Visits, hospitalizations, relapses and inactivity days over the 12 weeks
Overall cohort PS-matched cohort
Group A Group B Difference
Group B – Group A
p Group A Group B Difference
Group B – Group A
p
n. GP Visits mean (±SE) 0.84 (±0.09) 0.38 (±0.12) -0.46 <0.001 0.85 (±0.15) 0.38 (±0.12) -0.47 <0.001
Specialist visits mean (±SE) 0.66 (±0.08) 0.28 (±0.07) -0.38 <0.001 0.68 (±0.11) 0.28 (±0.07) -0.40 <0.001
n. Hospitalizations mean (±SE) 0.13 ± 0.04 0.08 ± 0.04 -0.05 0.372 0.15 ± 0.06 0.08 ± 0.04 -0.08 0.11
Days of Hospitalizations mean
(±SE)
0.19 ± 0.07 0.08 ± 0.04 -0.12 0.348 0.28 ± 0.12 0.08 ± 0.04 -0.20 0.09
n. Relapses mean (±SE) 0.53 (±0.08) 0.28 (±0.07) -0.26 0.106 0.53 (±0.12) 0.28 (±0.07) -0.25 0.12
Days of inactivity mean (±SE) 1.62 (±0.26) 0.68 (±0.20) -0.95 0.088 1.53 (±0.37) 0.68 (±0.20) -0.85 0.12
Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day
GP general practitioner, [95 % CI confidence interval], p refers to Wilcoxon rank-sum test
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Moreover, the mean cost for rescue medications per pa-
tient was € 35.24 in group A, and € 18.73 in group B, re-
spectively, with a difference of - € 16.51 in favour of group
B. The mean costs of the treatments per patient consider-
ing the ex-manufactory pack prices and the adherence
were € 36.60 in group A, and € 78.37 in group B. Overall,
the mean total cost per patient during the study period
was € 443.97 in group A, and € 281.11 in group B, with a
difference of - €162.86 in favor of group B.
No relevant side effect was reported in both groups of
patients. Transient hoarseness was recorded in two pa-
tients in group B and in one patient of group A, while
transient tachycardia was recorded in two patients of
group A.
Discussion
Asthma is a disease characterized by variable degree of air-
way obstruction which is mainly related to variable degree
of airway inflammation. In persistent mild-to-moderate
asthma a therapeutic strategy based on regular assumption
of ICS, or ICS/LABA is recommended in order to prevent
and/or avoid the occurrence of asthma relapses.
Several factors can affect the results of different treat-
ments, such as: the pharmacological characteristics of
the prescribed molecules; the handling characteristics of
the inhaler devices used for the drug delivery; the re-
quired frequency of daily inhalations for a 24 h efficacy
of treatment(s); the patient’s adherence to treatment.
Also the cost of treatments is progressively regarded
as a factor which can significantly contribute to pre-
cise the economic profile of different treatments, and
then to compare their convenience, particularly from
the National Health Service perspective.
The present study was an observational, retrospective
analysis aimed to compare the costs of mild-to-moderate
asthmatic patients assuming Fluticasone furoate/Vilanterol
once-a-day or Beclomethasone dipropionate/Formoterol
b.i.d over a 12-week period.
Both treatments were effective in improving lung
function significantly, particularly when the difference
calculated from baseline was measured as FEV1 % pre-
dicted. When the results obtained in group A and B
were compared, the improvement obtained in group B
proved significantly higher both in terms of absolute
FEV1 and FEV1 % predicted.
The trend in favour of treatment B was also confirmed
by the cost analysis.
In general terms, the cost analysis showed a tendency
towards a clear reduction of mean total costs in patients
treated with Fluticasone furoate/Vilanterol 92/22 μg
Table 3 Difference between FEV1 values at baseline (T0) and after 12 weeks (T1) in groups A and B
Group A Group B DIfference
Group B – Group A
T0 T1 Difference
T1 – T0





FEV1 (L) mean (±SE) 2.52 (±0.13) 2.62 (±0.12) 0.10 0.519 2.51 (±0.12) 2.72 (±0.13) 0.21 0.229 0.11 0.007
FEV1 (%), mean (±SE) 82.40 (±1.63) 87.08 (±1.58) 4.68 0.043 81.93 (±2.00) 89.50 (±2.64) 7.57 0.009 2.89 0.04
T0 =at baseline, before Beclomethasone dipropionate/Formoterol and Fluticasone furoate/Vilanterol treatment
T1 = after 12 weeks of Beclomethasone dipropionate/Formoterol and Fluticasone furoate/Vilanterol treatment
Forced expiratory volume in 1 s, litres, FEV1 (L)
Forced expiratory volume in 1 s, predicted values, FEV1(%)
[95 % CI, confidence interval]
p refers to Wilcoxon rank-sum test
Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day
Table 4 Estimate of the resource costs for the entire cohort and of the PS-matched cohort over the study period (€/per patient/
12 weeks)
Overall cohort (Euro) PS-matched cohort (Euro)
Group A Group B Difference
Group B – Group A
p Group A Group B Difference
Group B – Group A
p
Cost of GP visits
mean (±SE)
12.79 (±1.43) 5.68 (±1.77) -7.11 <0.001 12.88 (±2.27) 5.68 (±1.77) -7.20 <0.001
Cost of specialist
visits mean (±SE)




274.55 (±82.76) 172.65 (±98.18) -101.90 0.396 345.30
(±133.23)
172.65 (±98.18) -172.65 0.98
Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day
GP general practitioner, [95 % CI confidence interval], p refers to Wilcoxon rank-sum test
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once-a-day. The hospitalization cost, which is the main
component of cost, dropped by 50 % with Fluticasone
furoate/Vilanterol 92/22 μg once-a-day. Unfortunately,
due to both a certain dispersion of data occurring during
the limited duration of the study in a small sample of
subjects, and to the low frequency of hospitalization
events over this short period of time, the comparison
between the two groups in terms of hospitalization cost
did not reach the statistical significance.
In particular, even calculated over this limited period
of investigation, the number of GP and Specialist consul-
tations was significantly lower in patients treated with
Fluticasone furoate/Vilanterol. Correspondingly, the cost
due to visits (i.e. GP and Specialist visits) and to extra-
medications (rescue medications) needed for facing re-
lapses (such as, oral steroids and antibiotics) were also
significantly lower in this group, thus confirming the
substantial decrease of asthma impact during Flutica-
sone furoate/Vilanterol treatment.
Even if both ICS/LABA combined treatments are
regarded as highly effective and safe in persistent asthma
[5–10], nonetheless they seem characterized by a different
profile in terms of their economic impact on mild-to-
moderate asthma patients. On the other hand, Formoterol
and Vilanterol are characterized by different pharmaco-
kinetics and pharmacodinamics, as well as Beclometha-
sone dipropionate and Fluticasone furoate are [19–21].
The corresponding fixed combinations obviously reflect
these pharmacological peculiarities that lead to different
clinical aspect of their action and utilization, such as the
higher selectivity and persistency on steroid receptors in
favour of Fluticasone furoate, together with the higher se-
lectivity and a persistency on ß2- receptors in favour of
Vilanterol. Basically, these peculiarities are those which
consent the 24-h therapeutic effect of the Fluticasone
furoate/Vilanterol combination and then the once-a-day
assumption, which likely leads to a better patients’ adher-
ence to a long-term therapeutic strategy as confirmed in
the present paper over a 12-week period.
The present study has some limits: the short duration
of the investigation (12 weeks only) and the relative
small number of subjects included. Moreover, the study
is a monocentric investigation. On the other hand, some
points of strength consist in the automatic selection of
subjects from a general data-base and in the use of the
propensity score matching method for assessing and
comparing the outcomes, which assured a strictly object-
ive system for comparison between the two subjects’
samples.
Conclusions
The present study showed that the once-daily inhalation
of combined Fluticasone furoate/Vilanterol 92/22 μg has
the clear potential for enhanced clinical outcomes and
reduced costs when compared to Beclomethasone dipro-
pionate/Formoterol 100/6 μg b.i.d.
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